Frazier Life Sciences Management, L.P. Ultragenyx Pharmaceutical Inc. Transaction History
Frazier Life Sciences Management, L.P.
- $2.36 Billion
- Q3 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 983,715 shares of RARE stock, worth $32.5 Million. This represents 1.25% of its overall portfolio holdings.
Number of Shares
983,715
Previous 983,715
-0.0%
Holding current value
$32.5 Million
Previous $35.8 Million
17.27%
% of portfolio
1.25%
Previous 1.89%
Shares
4 transactions
Others Institutions Holding RARE
# of Institutions
351Shares Held
88.3MCall Options Held
2.23MPut Options Held
1.06M-
Vanguard Group Inc Valley Forge, PA10.1MShares$335 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$185 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY4.01MShares$133 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA3.77MShares$125 Million0.33% of portfolio
-
State Street Corp Boston, MA3.69MShares$122 Million0.0% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $2.32B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...